Journal
JOURNAL OF VIROLOGY
Volume 89, Issue 4, Pages 2425-2429Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.02752-14
Keywords
-
Categories
Funding
- NIH [R01 AI077376-01, R01 AI077376]
- Office of Research Infrastructure Programs (ORIP) [P51 RR000167]
- component of the National Institutes of Health (NIH)
- Research Facilities Improvement Program [RR15459-01, RR020141-01]
- University of Wisconsin's Medical Scientist Training Program (MSTP) [T32 GM008692]
- National Research Service Award (NRSA) through the Microbes in Health and Disease (MHD) training program at the University of Wisconsin [T32 AI055397]
- University of Wisconsin Department of Pathology and Laboratory Medicine
- WNPRC
Ask authors/readers for more resources
In 49 patients with known Ebola virus disease outcomes during the ongoing outbreak in Sierra Leone, 13 were coinfected with the immunomodulatory pegivirus GB virus C (GBV-C). Fifty-three percent of these GBV-C+ patients survived; in contrast, only 22% of GBV-C- patients survived. Both survival and GBV-C status were associated with age, with older patients having lower survival rates and intermediate-age patients (21 to 45 years) having the highest rate of GBV-C infection. Understanding the separate and combined effects of GBV-C and age on Ebola virus survival may lead to new treatment and prevention strategies, perhaps through age-related pathways of immune activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
